Sam Rodriguez claims to have proposed the concept of Focused Research Organizations (FROs) for science projects that are too large for academia but not commercially viable for for-profit companies.

A paper detailing a discovery made by Edison Scientific's AI agent system, Robin, was published in the journal Nature.

The Cosmos AI agent system includes a built-in orchestrator for self-orchestration and uses 'world models' for sophisticated context management over hundreds of subagent runs.

AI drug discovery startups like Chai Discovery and Isomorphic primarily focus on creating novel molecules and then partnering with large pharmaceutical companies for development, rather than developin...

In Australia and China, the approval process for early-stage clinical trials is decentralized, allowing individual trial centers to grant approvals.

The original version of the Cosmos AI agent could run for 6 to 12 hours, write 45,000 lines of code, and read 1,500 papers in a single execution.

DeepMind's AlphaFold is a notable exception to the history of AI overpromising in drug discovery, as it has significantly changed molecular design by providing protein structures.

Eroom's Law in medicine describes the observation that the inflation-adjusted cost to develop a new drug has historically doubled every nine years.

Edison Scientific's for-profit entity has raised $70 million, and its associated non-profit, Future House, has raised an additional, larger amount.

The complete wiring diagram of the human brain has not yet been mapped by scientists.

Sam Rodriguez predicts that future pharmaceutical companies will operate with much leaner organizational structures due to AI-driven efficiencies.

Sam Rodriguez predicts that AI will enable pharmaceutical companies to pursue a significantly larger number of drug programs in parallel without increasing headcount.

Andrew White, co-founder of Future House, previously worked with OpenAI on GPT-4 and was a professor at the University of Rochester.

Companies working on generating novel molecules for drug discovery include Chai Discovery, Isomorphic, Boltz, Lambda Labs, and Profluent Bio.

Edison Scientific claims its models use significantly more test-time compute specifically to minimize hallucinations compared to general-purpose models.

Sam Rodriguez asserts that pharmaceutical companies do not want to be locked into a single foundation model provider due to the rapidly shifting performance leadership between companies like OpenAI an...

Due to more efficient clinical trial approval processes, many U.S. biotech companies are conducting their trials in Australia and China.

Sam Rodriguez believes the ultimate measure of success for AI in the pharmaceutical industry will be an approved drug resulting from a pivotal Phase 3 clinical trial, not just intermediate discoveries...

Since its launch, the Cosmos AI agent has been used to make approximately 20,000 to 30,000 novel scientific findings.

Sam Rodriguez estimates that users of the Cosmos AI agent system have made approximately 20,000 to 30,000 novel scientific findings.